Back to home

Easyhaler® is the first inhaler range to be certified as carbon neutral

Insights | 18/05/2021
Easyhaler<sup>®</sup> is the first inhaler range to be certified as carbon neutral

Prescribing information available here

 

Let's keep the planet breathing

Orion is proud to announce that the Easyhaler® Range has been certified as carbon neutral. Carbon neutrality is achieved by minimising CO2 emissions across the entire supply chain and throughout our products’ lifecycle. Remaining emissions are offset through projects that protect the world’s lungs: forests in the Amazon and the UK.

A growing awareness of climate change is driving whole nations and industries to cut carbon emissions.1 This is also true for healthcare. Climate impact is becoming an increasingly important concern for healthcare providers and patients alike when choosing a therapy for asthma or COPD.

 

Playing our part at Orion Pharma

For Orion, the fight against climate change means concrete action to minimise greenhouse gas emissions across the supply chain and throughout our products’ lifecycle. To push climate action in the pharma industry, Orion Pharma is committed to reaching company wide carbon neutrality by 2030.

The fight against climate change has not just started for Orion Pharma. We have sought for innovative ways to help push the medical industry forward to be more environmentally sustainable. One of the original Easyhaler® development objective was to create a propellant free inhaler for environmental reasons.

The carbon footprint of a single Metered Dose Inhaler (MDI) can be anywhere from 10 to 37 times higher than that of a Dry Powder Inhaler (DPI) because of the potent greenhouse gases used as propellants in MDIs.2 Orion Pharma are proud of our commitments to protect the environment, as a company based in Finland where 75% of the countries land area is forest3 we appreciate the beauty and benefits that come from protecting the natural world. By only manufacturing Dry Power Inhalers (DPIs), we are playing our part in protecting the planet by consistently seeking to minimise our carbon footprint. To this day, Orion Pharma has never manufactured a pMDI.

Just because Easyhaler® doesn’t use propellants, does not mean that it doesn’t have a carbon footprint. Almost all of our actions as human beings have a carbon footprint because nearly everything we consume or use is associated with greenhouse gas emissions during that product or services lifetime.4 To calculate a carbon footprint a full lifecycle assessment should be conducted to identify what different GHG have been emitted as a result of the creation, use and disposal of that product.5

 

Life Cycle Assessment of Easyhaler®

The carbon footprint of Easyhaler® was assessed for the first time in 2020.6 After identifying areas for improvement in the first assessment, in 2021, Orion conducted a comprehensive life cycle assessment (LCA) for the whole Easyhaler ® product family.7 It covered raw material extraction, upstream materials preparation, transportation, manufacture, processing and assembly, distribution, and disposal. Based on the LCA, the average cradle to grave carbon footprint for an Easyhaler® product is 0.580kg CO2 equivalent.7

Now that a full life cycle assessment has been completed for the Easyhaler® range, carbon neutrality for Easyhaler® is achieved by first minimising the inhalers’ CO2e emissions across the product’s life cycle, and then offsetting the remaining emissions. Offsetting is done by supporting reforestation and forest protection projects in the UK and in the Amazon.8

 

EASYHALER® PRODUCT FAMILY: CERTIFIED AS CARBON NEUTRAL 

device-images-for-carbon-neutral.png

carbon-neutral.png

 

An opportunity to re-engage with patients

Orion Pharma advocate that patient safety, efficacy and choice must remain the primary drivers in deciding the most suitable device for respiratory patients. We want to work with clinicians to support them in having discussions with patients around their preferences on inhaler devices. All parties can then make an informed choice about whether they would be suitable to move onto an inhaler that not only meets their clinical needs in line with product indication, but also aligns with their environmental values.

PATIENTS DESERVE CHOICE, AND THE EASYHALER RANGE GIVES THEM THAT.

 

Read More:

References

  1. World Economic Forum, 2019. Accessed on 18th May 2021 from: https://www.weforum.org/agenda/2019/12/countries-companies-net-zero-carbon-emissions/
  2. Montreal protocol on substances that deplete the ozone layer. Medical and chemicals technical options committee . Assessment report 2018 . Accessed 13 th May from :
    https://ozone.unep.org/sites/default/files/2019 05/TEAPAS98.pdf
  3. Carbon life cycle assessment report for Orion Corporation, Orion Pharma. Executive
    summary. Carbon Footprint Ltd 2020. Available at:
    https://www.orion.fi/globalassets/documents/orion group/sustainability/2020-
    orion-
    pharma-product-footprint-exec-summary.pdf
  4. Ministry of Agriculture and Forestry of Finland. N.D. Forest resources in Finland. Accessed
    on 13 th May 2021 from: https://mmm.fi/en/forests/forestry/forest-resources#:~:text=Forests%20cover%20more%20than%2075,per%20cent%20is%20privately%20owned
  5. Berners Lee, M., 2020. How to calculate the carbon footprint of everything. The Sunday
    Times. Accessed on 13 th May 2021 from: https://www.thetimes.co.uk/article/how-to
    -calculate-the-carbon-footprint-of-everything
    j98nbv9jm #:~:text=Almost%20everything%20we%20do%20has,it%20releases%20into %20the%20atmosphere
  6. Center for Sustainable Systems, University of Michigan, 2020. “Carbon Footprint
    Factsheet.” Pub. No. CSS09 05. Accessed on 13 th May 2021 from :
    http://css.umich.edu/sites/default/files/Carbon%20Footprint_CSS09 05_e2020_0.pdf
  7. Carbon life cycle assessment report for Orion Corporation, Orion Pharma. Executive
    summary. Carbon Footprint Ltd 2021. Available at: 2021_04-orion-pharma-product
    -footprint-lca-executive-summary-v1.0.pdf
  8. Carbon Footprint Assessment for Orion Corporation, Orion Pharma. https://www.orion.fi/vastuullisuus/tarinoita-vastuullisuudesta/
    hiilijalanjaljen-arviointi-orionin-kuivajauheinhalaattoreille/

 

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Orion Pharma (UK) Ltd on 01635 520300.

 

May 2021/RESP-807(2)a

ORIONPHARMA.CO.UK

 

Full prescribing information available here

 

MAY 2021 / RESP-330b(3)

 

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Orion Pharma (UK) Ltd on 01635 520300.

Orion Pharma (UK) Ltd, Abbey Gardens, 4 Abbey Street, Reading, RG1 3BA, UK | Tel: +44 1635 520 300 | February 2021 / RESP-330(1)
Policies Contact us Orion Corporation 2021